Quick Answer
Prime Medicine, Inc. reported Total Revenue of $4.63 million for fiscal year 2025.
Prime Medicine, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $4.63M +55.3% |
$2.98M | $0.00 | $0.00 | $0.00 -100.0% |
$5.21M |
| Revenue (ASC 606) | $4.63M +55.3% |
$2.98M | $0.00 | $0.00 | $0.00 -100.0% |
$5.21M |
| Net Income | -$201.14M -2.7% |
-$195.88M +1.1% |
-$198.13M -62.6% |
-$121.82M +26.3% |
-$165.37M -4749.5% |
-$3.41M |
| Diluted EPS | -$1.35 +18.2% |
-$1.65 +24.3% |
-$2.18 +48.0% |
-$4.19 +70.5% |
-$14.19 -642.9% |
-$1.91 |
| Total Assets | $342.73M +15.2% |
$297.51M +53.5% |
$193.85M -46.2% |
$360.31M +19.4% |
$301.86M | — |
| Cash and Equivalents | $63.03M -65.5% |
$182.48M +338.9% |
$41.57M -77.8% |
$187.62M +1.2% |
$185.42M +401.5% |
$36.98M |
| Stockholders Equity | $120.87M -21.1% |
$153.15M +15.1% |
$133.07M -57.9% |
$316.27M +302.4% |
-$156.24M -6782.6% |
$2.34M +190.0% |
| R&D Expense | $160.64M +3.4% |
$155.29M +5.0% |
$147.91M +70.5% |
$86.72M +22.9% |
$70.55M +2267.4% |
$2.98M |
| Operating Income | -$208.35M -2.9% |
-$202.47M +1.1% |
-$204.79M -75.7% |
-$116.54M -38.0% |
-$84.47M -8963.7% |
-$932.0K |
| Shares Outstanding | 180.51M +37.6% |
131.16M +34.7% |
97.38M +0.2% |
97.21M +199.9% |
32.41M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.23M | +486.1% | +9.9% |
| Revenue (ASC 606) | September 30, 2025 | $1.23M | +486.1% | +9.9% |
| Net Income | September 30, 2025 | -$50.58M | +3.7% | +3.8% |
| Diluted EPS | September 30, 2025 | -$0.32 | +27.3% | +22.0% |
| Total Assets | September 30, 2025 | $385.01M | +15.7% | +38.0% |
| Cash and Equivalents | September 30, 2025 | $71.40M | -39.5% | +32.7% |
| Stockholders Equity | September 30, 2025 | $161.82M | -14.6% | +165.9% |
| R&D Expense | September 30, 2025 | $43.99M | +9.0% | +6.3% |
| Operating Income | September 30, 2025 | -$53.97M | +0.5% | -1.1% |
| Shares Outstanding | September 30, 2025 | 180.31M | +37.5% | +34.1% |
- Prime Medicine, Inc. reported Total Revenue of $4.63 million for fiscal year 2025.
- Prime Medicine, Inc. showed an increase of +55.3% in Total Revenue compared to the prior fiscal year.
- Prime Medicine, Inc. reported Revenue (ASC 606) of $4.63 million for fiscal year 2025.
- Prime Medicine, Inc. showed an increase of +55.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Prime Medicine, Inc. reported Net Income of -$201.14 million for fiscal year 2025.
- Prime Medicine, Inc. showed a decrease of -2.7% in Net Income compared to the prior fiscal year.
- Prime Medicine, Inc. reported Diluted EPS of $1.35 per share (loss) for fiscal year 2025.
- Prime Medicine, Inc. showed an increase of +18.2% in Diluted EPS compared to the prior fiscal year.
- Prime Medicine, Inc. reported Total Assets of $342.73 million for fiscal year 2025.
- Prime Medicine, Inc. showed an increase of +15.2% in Total Assets compared to the prior fiscal year.
- Prime Medicine, Inc. reported Cash and Equivalents of $63.03 million for fiscal year 2025.
- Prime Medicine, Inc. showed a decrease of -65.5% in Cash and Equivalents compared to the prior fiscal year.
- Prime Medicine, Inc. reported Stockholders Equity of $120.87 million for fiscal year 2025.
- Prime Medicine, Inc. showed a decrease of -21.1% in Stockholders Equity compared to the prior fiscal year.
- Prime Medicine, Inc. reported R&D Expense of $160.64 million for fiscal year 2025.
- Prime Medicine, Inc. showed an increase of +3.4% in R&D Expense compared to the prior fiscal year.
- Prime Medicine, Inc. reported Operating Income of -$208.35 million for fiscal year 2025.
- Prime Medicine, Inc. showed a decrease of -2.9% in Operating Income compared to the prior fiscal year.
- Prime Medicine, Inc. reported Shares Outstanding of 180.51 million shares for fiscal year 2025.
- Prime Medicine, Inc. showed an increase of +37.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: